title: Predicting therapeutic efficacy of intravenous immunoglobulin (IVIG) in individual patients with relapsing remitting multiple sclerosis (RRMS) by functional genomics.
abstract: OBJECTIVE
  Only a fraction of patients do benefit from disease modifying treatments in RRMS and data on IVIG are controversial, it has been suggested that there is a subpopulation of patients with good clinical response to IVIG.
  
  
  METHODS
  In the prospective, multicenter, open label, exploratory study RRMS patients receiving IVIG therapy were genotyped and several immune parameters were collected.
  
  
  RESULTS
  To distinguish between potential responders and non-responders each of the observed genotypes was combined with the corresponding scores of 65 immune parameters in a stepwise approach. Non-responders were defined as being positive for 4 or more out of 9 individual scores. Responders scored either 0 or 1, while non-responders scored between 7 and 9 (p=1.2∗10(-7)).
  
  
  CONCLUSIONS
  In summary, combination of genomic and functional immune parameters allowed prospective discrimination between responders and non-responders towards IVIG therapy in this learning panel of RRMS patients and will be confirmed in a validation study.
authors.affiliation: Medical University Innsbruck, Clinical Dept. of Neurology, Anichstrasse 35, 6020 Innsbruck, Austria.
authors.forename: Thomas
authors.initials: T
authors.lastname: Berger
authors.affiliation: Krankenhaus Nordwest GmbH, Dept. Neurology, Steinbacher Hohl 2-26, 60488 Frankfurt, Germany.
authors.forename: Christian
authors.initials: C
authors.lastname: Jacobi
authors.affiliation: Jewish Hospital Berlin, Heinz Galinski Strasse 1, 13347 Berlin, Germany.
authors.forename: Judith
authors.initials: J
authors.lastname: Haas
authors.affiliation: General Hospital Linz GmbH, Krankenhausstrasse 9, 4021 Linz, Austria.
authors.forename: Gerhard
authors.initials: G
authors.lastname: Ransmayr
authors.affiliation: General Hospital Linz GmbH, Krankenhausstrasse 9, 4021 Linz, Austria.
authors.forename: Michael
authors.initials: M
authors.lastname: Guger
authors.affiliation: University of Rostock, Dept. of Neurology, Neuroimmunology Unit, Gehlsheimer Strasse 20, 18147 Rostock, Germany.
authors.forename: Uwe K
authors.initials: UK
authors.lastname: Zettl
authors.affiliation: Medical University Innsbruck, Clinical Dept. of Neurology, Anichstrasse 35, 6020 Innsbruck, Austria.
authors.forename: Franziska
authors.initials: F
authors.lastname: Di Pauli
authors.affiliation: Octapharma Pharmazeutika Produktionsges.m.b.H., Oberlaaer Strasse 235, 1100 Vienna, Austria.
authors.forename: Birgit
authors.initials: B
authors.lastname: Taumberger
authors.affiliation: Octapharma Pharmazeutika Produktionsges.m.b.H., Oberlaaer Strasse 235, 1100 Vienna, Austria.
authors.forename: Stefan
authors.initials: S
authors.lastname: Wietek
authors.affiliation: Heidelberg University Hospital, Institute for Immunology, Im Neuenheimer Feld 305, 69120 Heidelberg, Germany.
authors.forename: Stefan
authors.initials: S
authors.lastname: Meuer
authors.affiliation: Innsbruck Medical University, Neurological Research Laboratory, Anichstrasse 35, A-6020 Innsbruck, Austria.
authors.forename: Markus
authors.initials: M
authors.lastname: Reindl
authors.affiliation: Heidelberg University Hospital, Institute for Immunology, Im Neuenheimer Feld 305, 69120 Heidelberg, Germany. Electronic address: Thomas.Giese@immu.uni-heidelberg.de.
authors.forename: Thomas
authors.initials: T
authors.lastname: Giese
mesh_terms: D016207:Cytokines / Q000097:blood; D004185:Disability Evaluation; D005260:Female; D005434:Flow Cytometry; D005838:Genotype; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use*; D007155:Immunologic Factors / Q000627:therapeutic use*; D008297:Male; D020529:Multiple Sclerosis, Relapsing-Remitting / Q000188:drug therapy* / Q000235:genetics* / Q000473:pathology; D010597:Pharmacogenetics; D020641:Polymorphism, Single Nucleotide; D011446:Prospective Studies; D012333:RNA, Messenger / Q000378:metabolism; D015203:Reproducibility of Results
chemical_list: D016207:Cytokines; D016756:Immunoglobulins, Intravenous; D007155:Immunologic Factors; D012333:RNA, Messenger
keywords: Individualized immunotherapy; Intravenous immunoglobulin (IVIG); Prospective clinical study; Prospective responder discrimination; Relapsing-remitting multiple sclerosis (RRMS)